Science Current Events | Science News | Brightsurf.com
 

Combining therapies can improve survival for early-stage breast cancer patients

April 04, 2007
Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression—treatment to stop the ovaries from functioning—did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.

Survival rates improve for patients with early-stage breast cancer who receive a single method of treatment—either tamoxifen, ovarian suppression, or chemotherapy. Two international studies by the Adjuvant Breast Cancer Trials Collaborative Group were designed to test whether combining these treatments would provide additional benefits.

Judith Bliss of The Institute of Cancer Research in Sutton, England, and colleagues conducted two randomized controlled phase III clinical trials of 3,854 women with early-stage breast cancer, all of whom were treated with tamoxifen for five years. In the first trial, nearly half of the 2,144 premenopausal women were randomly assigned to receive ovarian suppression, and the other half did not. Some also received chemotherapy. In the second trial, 1,991 patients were randomly assigned to receive chemotherapy, and the other half were not. Some premenopausal women also had ovarian suppression.

The researchers found that chemotherapy treatment resulted in a modest yet sustained improvement in both relapse-free and overall survival. These improvements were especially strong in women younger than 50 years and in premenopausal women who did not receive ovarian suppression.

They also found that neither relapse-free survival nor overall survival was affected by the addition of ovarian suppression. However, the results indicate a possible benefit of ovarian suppression when given along side tamoxifen for a small group of women younger than 40 years who have ER-positive tumors (tumors that need estrogen to grow), especially when they are not receiving chemotherapy. The researchers called for further research into this group of breast cancer patients.

"Relapse-free survival benefits emerged early and were maintained, whereas overall survival benefits did not emerge for at least 5 years, reinforcing the need for long-term follow-up in chemotherapy trials," the authors write. The trials add "to the limited data available on the effects of combining long-term tamoxifen, chemotherapy, and ovarian ablation of suppression."

In an accompanying editorial, Kathleen Pritchard, M.D., of Toronto Sunnybrook Regional Cancer Centre, describes how the trial could have found more interesting results if there had been more data on patients' ER status. "Most of all, however, these studies stress the importance of establishing processes to ensure the availability of archived tumor specimens for all randomized adjuvant trials. The era in which such large important trials should be carried out without the archived correlational tumor samples is over."

Journal of the National Cancer Institute


Related Tamoxifen Current Events and Tamoxifen News Articles


Scientists discover a new role for estrogen in the pathology of breast cancer
Scientists have discovered a previously unknown mechanism by which estrogen prepares cells to divide, grow and, in the case of estrogen-positive breast cancers, resist cancer drugs.

The 'Angelina Effect' was not only immediate, but also long-lasting
Referrals for genetic counselling and testing for breast cancer risk more than doubled across the UK after actress Angelina Jolie announced in May last year that she tested positive for a BRCA1 gene mutation and underwent a double mastectomy.

WIH Researchers Examine Role of Hormone in Patient Responses to Ovarian Cancer Treatment
Researchers at Women & Infants Hospital of Rhode Island recently published the results of an investigation into how we might better tailor therapy for ovarian cancer.

Exposure to dim light at night may make breast cancers resistant to tamoxifen
For rats bearing human breast tumors, exposure to dim light at night made the tumors resistant to the breast cancer drug tamoxifen, according to data published in Cancer Research, a journal of the American Association for Cancer Research.

Total darkness at night is key to success of breast cancer therapy -- Tulane study
Exposure to light at night, which shuts off nighttime production of the hormone melatonin, renders breast cancer completely resistant to tamoxifen, a widely used breast cancer drug, says a new study by Tulane University School of Medicine cancer researchers.

What if hormones aren't fuel for the fire after all?
It's no wonder that breast cancer ranks highest among women's health concerns. Over 235,000 cases of breast cancer are diagnosed annually in the United States, with almost 40,000 deaths attributable to the disease.

New skin gel fights breast cancer without blood clot risk
A gel form of tamoxifen applied to the breasts of women with noninvasive breast cancer reduced the growth of cancer cells to the same degree as the drug taken in oral form but with fewer side effects that deter some women from taking it.

Study Shows Anti-Androgen Receptor Therapy for Triple-Negative Breast Cancer May Benefit More Than Just High-Androgen Receptor Tumors
Triple-negative breast cancers do not benefit from the targeted therapies that have greatly improved the survival of patients with other subtypes of breast cancer.

Possible new weapon found for fighting some types of breast cancer
Researchers believe they have discovered one reason why some women with estrogen receptor-positive breast cancer may respond poorly or only temporarily to estrogen-blocking drugs such as tamoxifen.

Potential Cholesterol Lowering Drug Has Breast Cancer Fighting Capabilities, MU Researcher Finds
Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of breast cancer, but also can kill the cancerous cells.
More Tamoxifen Current Events and Tamoxifen News Articles

Tamoxifen and Breast Cancer (Yale Fastback Series)

Tamoxifen and Breast Cancer (Yale Fastback Series)
by Michael W. DeGregorio (Author), Valerie J. Wiebe (Author)


A discussion of the diagnosis of breast cancer and the risks, benefits and limitations of treatment alternatives, particularly tamoxifen. This edition contains information on developments in the use of tamoxifen, especially in the results of the Breast Cancer Prevention Trial.

Tamoxifen: Pioneering Medicine in Breast Cancer (Milestones in Drug Therapy)

Tamoxifen: Pioneering Medicine in Breast Cancer (Milestones in Drug Therapy)
by Philipp Y. Maximov (Author), Russell E. McDaniel (Author), V. Craig Jordan (Author)


Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the...

Dr. Susan Love's Breast Book, 5th Edition (A Merloyd Lawrence Book)

Dr. Susan Love's Breast Book, 5th Edition (A Merloyd Lawrence Book)
by Susan M. Love MD (Author), Karen Lindsey (Contributor)


Dr. Susan Love's Breast Book has long been the bible for the newly diagnosed. In this completely revised fifth edition, it also becomes a guide for those at risk of getting breast cancer, survivors interested in the consequences of their treatment, and anyone who wants to understand the new research about how the local environment influences the manifestations and treatments of many different kinds of breast cancer. Major advances being made in genetic research today mean that prevention and treatment can work not only to get rid of mutated cells (through chemo or surgery), but also to change the environment around the cells (through hormone therapy, exercise, and stress reduction). Among other promising developments discussed are advances in imaging, recognition of breast density as a...

Tamoxifen: A guide for clinicians and patients

Tamoxifen: A guide for clinicians and patients
by V. Craig Jordan (Editor), Nancy G. Brinker (Editor)


Book by

Tamoxifen nel trattamento del carcinoma mammario: Studio dei fattori predittivi di risposta (Italian Edition)

Tamoxifen nel trattamento del carcinoma mammario: Studio dei fattori predittivi di risposta (Italian Edition)
by Laura Bertolaso (Author)


Il tamoxifen è un farmaco ampiamente usato per il trattamento e la prevenzione del più frequente istotipo di tumore mammario, quello positivo per i recettori degli estrogeni. Nonostante i notevoli successi nella pratica clinica derivanti dall'impiego di tale farmaco, essi non riguardano ancora la totalità delle pazienti. Questo libro espone i promettenti seppur preliminari risultati di uno studio iniziato nel 2010 volto ad analizzare sperimentalmente i fattori molecolari e genetici a potenziale carattere predittivo nella determinazione della risposta terapeutica.

STRIPPED: Cancer, Culture, and the Cloud of Unknowing

STRIPPED: Cancer, Culture, and the Cloud of Unknowing
by Heather King (Author)


I'm a lawyer turned writer, a Catholic convert, and a sober alcoholic. In 2000, I was diagnosed with invasive breast cancer. The good news: a small tumor; the least advanced stage. Still, doctors recommended surgery, radiation, high-dose chemo, and five years of the aggressive hormone drug Tamoxifen.

Terrified of dying, yet determined to steer my own course, I began researching. I found that chemo could kill, radiation could cause secondary cancers, Tamoxifen had severe side effects, and long-term studies on any of those treatments was virtually nil.

STRIPPED is a memoir about coming to the decision to have the tumor surgically removed--and to forego all further treatment. To love this world with all my heart, even as I know I'll be leaving it one day, is to dwell at the...

Tamoxifen: Beyond the Antiestrogen

Tamoxifen: Beyond the Antiestrogen
by John A. Kellen (Author)


Tamoxifen has persisted as a widely accepted and administered drug for almost 25 years. Following the many scientific papers and books on the subject, it has remained a very intriguing substance. This, perhaps, is the reason for another monograph on Tamoxifen. It is regrettably true that overviews, even when up to date after exhaustive research - the shibboleth of our cultures -, rapidly lose relevance with the passage of time. Scientists can sometimes be pictured as deep sea divers, who plunge into the unknown in search of a hitherto unknown world. Their descent is exciting, but eventually they must come up for air and integrate their experiences with others who also had to resurface. This book intends to collect and, where possible, to collate recent, but sometimes seemingly unrelated...

Tamoxifen Concepts and Cancer: New Paradigms (Cancer Etiology, Diagnosis and Treatments: Pharmacology - Research, Safety Testing and Regulation)

Tamoxifen Concepts and Cancer: New Paradigms (Cancer Etiology, Diagnosis and Treatments: Pharmacology - Research, Safety Testing and Regulation)
by Ramon Andrade De Mello (Editor)




  Tamoxifen & Breast Cancer
by Michael W. & Valerie J. Wiebe DEGREGORIO (Author)




  Tamoxifen prevents breast cancers--at a price. (Study of More than 7,000 Women).: An article from: Family Practice News
by Mitchel L. Zoler (Author)


This digital document is an article from Family Practice News, published by International Medical News Group on October 15, 2002. The length of the article is 629 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Tamoxifen prevents breast cancers--at a price. (Study of More than 7,000 Women).
Author: Mitchel L. Zoler
Publication: Family Practice News (Magazine/Journal)
Date: October 15, 2002
Publisher: International Medical News Group
Volume: 32 Issue: 20 Page: 35(1)

Distributed by Thomson...

© 2014 BrightSurf.com